{"url_path":"/sec/bbio/8-k/2026-07-02/item-3-03","section_key":"item-3-03","section_title":"Item 3.03 Material Modification to Rights of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-027445-index.html","accession_number":"0001140361-26-027445","cik":"0001743881","ticker":"BBIO","issuer_name":"BridgeBio Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1743881/0001140361-26-027445-index.html","primary_entity_key":"0001743881","primary_entity_name":"BridgeBio Pharma, Inc."},"word_count":135,"has_tables":true,"body_markdown":"Item 3.03.\n\nMaterial Modification to Rights of Security Holders.\n\n \n\nThe information set forth in Item 1.01 and Item 5.03 of this Current Report on Form 8-K is incorporated by reference into this Item\n3.03. Upon the issuance of the Preferred Stock, the rights of the holders of Common Stock became subject to, and may be adversely affected by, the rights, preferences and privileges of the holders of the Preferred Stock set forth in the\nCertificate of Designations, including with respect to the payment of dividends and the distribution of assets upon a liquidation, dissolution or winding up of the Company, and the Company’s ability to declare or pay dividends on, or to\nrepurchase or redeem, shares of Common Stock and other junior securities became subject to the restrictions set forth in the Certificate of Designations."}